Maintenance therapy for B-Chronic lymphocytic leukemia

Susan O'Brien, Neil Elliot Kay

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Although modern treatment options for B-chronic lymphocytic leukemia (CLL) produce high response rates, virtually all patients relapse, presumably due to the persistence of minimal residual disease (MRD). Novel approaches that maintain response and therefore delay growth of MRD may ultimately improve survival outcomes. In CLL, any type of continued therapy must be not only well tolerated but also convenient to ensure compliance. There has been some exploration of rituximab as maintenance therapy in CLL; however, given its limited clinical activity as a single agent, other options need to be studied. One such agent is the immunomodulatory drug lenalidomide, which has demonstrated clinical activity both in patients with relapsed or refractory CLL and in the frontline setting. Other attractive agents being explored in the maintenance setting include epigallocatechin gallate, curcumin, and the citrus pectin-derived galectin-3 inhibitor GCS-100. These naturally occurring compounds are well tolerated, and they inhibit survival signals in the microenvironment necessary for tumor development, making them well suited for evaluation as maintenance therapy for CLL.

Original languageEnglish (US)
Pages (from-to)22-31
Number of pages10
JournalClinical Advances in Hematology and Oncology
Volume9
Issue number1
StatePublished - Jan 2011

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Residual Neoplasm
Galectin 3
Therapeutics
Curcumin
Tumor Microenvironment
Survival
Compliance
Maintenance
Recurrence
Growth
Pharmaceutical Preparations

Keywords

  • Chronic lymphocytic leukemia
  • Immunomodulatory drugs
  • Lenalidomide
  • Maintenance therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Maintenance therapy for B-Chronic lymphocytic leukemia. / O'Brien, Susan; Kay, Neil Elliot.

In: Clinical Advances in Hematology and Oncology, Vol. 9, No. 1, 01.2011, p. 22-31.

Research output: Contribution to journalArticle

@article{35f403cd2ebf4eccaf6c948d03184e93,
title = "Maintenance therapy for B-Chronic lymphocytic leukemia",
abstract = "Although modern treatment options for B-chronic lymphocytic leukemia (CLL) produce high response rates, virtually all patients relapse, presumably due to the persistence of minimal residual disease (MRD). Novel approaches that maintain response and therefore delay growth of MRD may ultimately improve survival outcomes. In CLL, any type of continued therapy must be not only well tolerated but also convenient to ensure compliance. There has been some exploration of rituximab as maintenance therapy in CLL; however, given its limited clinical activity as a single agent, other options need to be studied. One such agent is the immunomodulatory drug lenalidomide, which has demonstrated clinical activity both in patients with relapsed or refractory CLL and in the frontline setting. Other attractive agents being explored in the maintenance setting include epigallocatechin gallate, curcumin, and the citrus pectin-derived galectin-3 inhibitor GCS-100. These naturally occurring compounds are well tolerated, and they inhibit survival signals in the microenvironment necessary for tumor development, making them well suited for evaluation as maintenance therapy for CLL.",
keywords = "Chronic lymphocytic leukemia, Immunomodulatory drugs, Lenalidomide, Maintenance therapy",
author = "Susan O'Brien and Kay, {Neil Elliot}",
year = "2011",
month = "1",
language = "English (US)",
volume = "9",
pages = "22--31",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "1",

}

TY - JOUR

T1 - Maintenance therapy for B-Chronic lymphocytic leukemia

AU - O'Brien, Susan

AU - Kay, Neil Elliot

PY - 2011/1

Y1 - 2011/1

N2 - Although modern treatment options for B-chronic lymphocytic leukemia (CLL) produce high response rates, virtually all patients relapse, presumably due to the persistence of minimal residual disease (MRD). Novel approaches that maintain response and therefore delay growth of MRD may ultimately improve survival outcomes. In CLL, any type of continued therapy must be not only well tolerated but also convenient to ensure compliance. There has been some exploration of rituximab as maintenance therapy in CLL; however, given its limited clinical activity as a single agent, other options need to be studied. One such agent is the immunomodulatory drug lenalidomide, which has demonstrated clinical activity both in patients with relapsed or refractory CLL and in the frontline setting. Other attractive agents being explored in the maintenance setting include epigallocatechin gallate, curcumin, and the citrus pectin-derived galectin-3 inhibitor GCS-100. These naturally occurring compounds are well tolerated, and they inhibit survival signals in the microenvironment necessary for tumor development, making them well suited for evaluation as maintenance therapy for CLL.

AB - Although modern treatment options for B-chronic lymphocytic leukemia (CLL) produce high response rates, virtually all patients relapse, presumably due to the persistence of minimal residual disease (MRD). Novel approaches that maintain response and therefore delay growth of MRD may ultimately improve survival outcomes. In CLL, any type of continued therapy must be not only well tolerated but also convenient to ensure compliance. There has been some exploration of rituximab as maintenance therapy in CLL; however, given its limited clinical activity as a single agent, other options need to be studied. One such agent is the immunomodulatory drug lenalidomide, which has demonstrated clinical activity both in patients with relapsed or refractory CLL and in the frontline setting. Other attractive agents being explored in the maintenance setting include epigallocatechin gallate, curcumin, and the citrus pectin-derived galectin-3 inhibitor GCS-100. These naturally occurring compounds are well tolerated, and they inhibit survival signals in the microenvironment necessary for tumor development, making them well suited for evaluation as maintenance therapy for CLL.

KW - Chronic lymphocytic leukemia

KW - Immunomodulatory drugs

KW - Lenalidomide

KW - Maintenance therapy

UR - http://www.scopus.com/inward/record.url?scp=79951479083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951479083&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 22

EP - 31

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 1

ER -